Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunjan L Shah

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|April 3, 2024
Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United StatesChendi Cui, Chaoling Feng, Ning Rosenthal, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 29, 2024
Influence of Obesity on the Efficacy and Toxicity of Patients Undergoing Autologous Hematopoietic Cell Transplantation for LymphomaAndrew Lin, Nicole Pearl, Jessica Flynn, et al.
Transplantation and Cellular Therapy|June 29, 2022
Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyMiguel-Angel Perales, Larry D Anderson, Tania Jain, et al.
Transplantation and Cellular Therapy|November 1, 2023
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyLarry D Anderson, Binod Dhakal, Tania Jain, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 21, 2017
Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Jonathan U Peled, et al.
Journal of the American Society for Mass Spectrometry|June 20, 2020
Jettison-MS of Nucleic Acid SpeciesPoguang Wang, Gunjan L Shah, Heather Landau, et al.
Blood Advances|May 16, 2025
Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data AnalysisAndrea Chung, Jason Shafrin, Sachin Vadgama, et al.
Blood Advances|July 8, 2022
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adultsIoannis Politikos, Carmen Lau, Sean M Devlin, et al.
Transplantation and Cellular Therapy|June 5, 2024
Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell TransplantationCarrie A Tan, Lauren Palen, Yiqi Su, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 4, 2019
Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometryRyan C Schofield, Heather J Landau, Sergio A Giralt, et al.
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|April 3, 2024
Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United StatesChendi Cui, Chaoling Feng, Ning Rosenthal, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 29, 2024
Influence of Obesity on the Efficacy and Toxicity of Patients Undergoing Autologous Hematopoietic Cell Transplantation for LymphomaAndrew Lin, Nicole Pearl, Jessica Flynn, et al.
Transplantation and Cellular Therapy|June 29, 2022
Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyMiguel-Angel Perales, Larry D Anderson, Tania Jain, et al.
Transplantation and Cellular Therapy|November 1, 2023
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyLarry D Anderson, Binod Dhakal, Tania Jain, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 21, 2017
Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Jonathan U Peled, et al.
Journal of the American Society for Mass Spectrometry|June 20, 2020
Jettison-MS of Nucleic Acid SpeciesPoguang Wang, Gunjan L Shah, Heather Landau, et al.
Blood Advances|May 16, 2025
Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data AnalysisAndrea Chung, Jason Shafrin, Sachin Vadgama, et al.
Blood Advances|July 8, 2022
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adultsIoannis Politikos, Carmen Lau, Sean M Devlin, et al.
Transplantation and Cellular Therapy|June 5, 2024
Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell TransplantationCarrie A Tan, Lauren Palen, Yiqi Su, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 4, 2019
Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometryRyan C Schofield, Heather J Landau, Sergio A Giralt, et al.
Pageof 13